JP7079729B2 - 異種タンパク質発現のためのプラスミド構築物及びその使用方法 - Google Patents
異種タンパク質発現のためのプラスミド構築物及びその使用方法 Download PDFInfo
- Publication number
- JP7079729B2 JP7079729B2 JP2018532285A JP2018532285A JP7079729B2 JP 7079729 B2 JP7079729 B2 JP 7079729B2 JP 2018532285 A JP2018532285 A JP 2018532285A JP 2018532285 A JP2018532285 A JP 2018532285A JP 7079729 B2 JP7079729 B2 JP 7079729B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- expression
- promoter
- expression plasmid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
Description
Claims (15)
- 式P-A-T-A´によって表される発現カセットを含む、発現プラスミド。
式中、
a)Pは発現プロモーターであり、
b)AはIL-12p35をコードし、
c)A´はIL-12p40をコードし、
d)Tは2Aリボソームスキップ調節因子をコードする。 - Pは、ヒトCMVプロモーター、サルCMVプロモーター、SV-40プロモーター、mPGKプロモーター、及びβアクチンプロモーターからなる群から選択される、請求項1に記載の発現プラスミド。
- 前記A-T-A´が、配列番号5、配列番号6、または配列番号7の核酸配列を含む、請求項1または2に記載の発現プラスミド。
- 式P-A-T-A´-T-Bまたは式P-B-T-A-T-A´によって表される発現カセットを含む、発現プラスミド。
式中、
a)Pは発現プロモーターであり、
b)AはIL-12p35をコードし、
c)A´はIL-12p40をコードし、
d)Bは少なくとも1つの腫瘍抗原と融合した少なくとも1つの遺伝子アジュバントをコードし、前記遺伝子アジュバントは、Flt3リガンド、LAMP-1、ヒトヒートショックタンパク質96、GM-CSF、及びCSF1受容体からなる群から選択され、
e)Tは翻訳修飾エレメントである。 - Pは、ヒトCMVプロモーター、サルCMVプロモーター、SV-40プロモーター、mPGKプロモーター、及びβアクチンプロモーターからなる群から選択される、請求項4に記載の発現プラスミド。
- 前記翻訳修飾エレメントは、2Aリボソームスキップ調節因子及び内部リボソーム進入部位(IRES)からなる群から選択される、請求項4または5に記載の発現プラスミド。
- 前記遺伝子アジュバントは、前記Flt3リガンドである、請求項4~6のいずれかに記載の発現プラスミド。
- 前記抗原は、NYESO-1抗原、OVA抗原、RNEU抗原、MAGE-A1抗原、MAGE-A2抗原、Mage-A10抗原、SSX-2抗原、Melan-A抗原、MART-1抗原、チロシナーゼ抗原、Gp100抗原、LAGE-1抗原、サバイビン抗原、hTERT抗原、PRS pan-DR抗原、B7-H6抗原、HPV E7抗原、HPV16 E6/E7抗原、HPV11 E6抗原、HPB6b/11 E7抗原、インフルエンザ HA抗原、インフルエンザ NA抗原、ポリオーマウイルス抗原、CEAペプチドCAP-1抗原、HCV-NS3抗原、及びHPVワクチンペプチドからなる群から選択される、請求項7に記載の発現プラスミド。
- 前記A-T-A´が、配列番号5、配列番号6、または配列番号7の核酸配列を含む、請求項4~8のいずれかに記載の発現プラスミド。
- 対象における腫瘍を治療するために使用され、
少なくとも1つの腫瘍内電気穿孔パルスを使用して、腫瘍内に送達される、請求項1~9のいずれかに記載の発現プラスミド。 - 前記腫瘍内電気穿孔パルスは200V/cm~1500V/cmの電界強度を有する、請求項10に記載の発現プラスミド。
- 前記対象はヒトである、請求項10に記載の発現プラスミド。
- 前記腫瘍は、メラノーマ、トリプルネガティブ乳癌、メルケル細胞癌、CTCL、及び頭頸部扁平上皮癌からなる群から選択される、請求項10に記載の発現プラスミド。
- 前記腫瘍内電気穿孔パルスは、電気化学インピーダンス分光法が可能な発生装置によって送達される、請求項10に記載の発現プラスミド。
- 式P-A-T-Bによって表される発現カセットを含む、発現プラスミド。
式中、
a)Pは発現プロモーターであり、
b)Aは免疫刺激性サイトカインをコードし、
c)Bは少なくとも1つの抗原と融合した遺伝子アジュバントをコードし、
d)Tは翻訳修飾エレメントである。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022083896A JP2022116129A (ja) | 2015-12-18 | 2022-05-23 | 異種タンパク質発現のためのプラスミド構築物及びその使用方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269702P | 2015-12-18 | 2015-12-18 | |
US62/269,702 | 2015-12-18 | ||
US201662375245P | 2016-08-15 | 2016-08-15 | |
US62/375,245 | 2016-08-15 | ||
PCT/US2016/067388 WO2017106795A1 (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022083896A Division JP2022116129A (ja) | 2015-12-18 | 2022-05-23 | 異種タンパク質発現のためのプラスミド構築物及びその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018537989A JP2018537989A (ja) | 2018-12-27 |
JP2018537989A5 JP2018537989A5 (ja) | 2020-01-09 |
JP7079729B2 true JP7079729B2 (ja) | 2022-06-02 |
Family
ID=59057754
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018532285A Active JP7079729B2 (ja) | 2015-12-18 | 2016-12-16 | 異種タンパク質発現のためのプラスミド構築物及びその使用方法 |
JP2022083896A Pending JP2022116129A (ja) | 2015-12-18 | 2022-05-23 | 異種タンパク質発現のためのプラスミド構築物及びその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022083896A Pending JP2022116129A (ja) | 2015-12-18 | 2022-05-23 | 異種タンパク質発現のためのプラスミド構築物及びその使用方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US11713467B2 (ja) |
EP (1) | EP3390643B8 (ja) |
JP (2) | JP7079729B2 (ja) |
KR (1) | KR20190031424A (ja) |
CN (1) | CN109642240A (ja) |
AU (2) | AU2016369608B2 (ja) |
CA (1) | CA3009123A1 (ja) |
IL (2) | IL299646A (ja) |
SG (2) | SG11201805162VA (ja) |
WO (1) | WO2017106795A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2981049A1 (en) | 2015-03-26 | 2016-09-29 | Oncosec Medical Incorporated | Combination of an immunostimulatory cytokine and a checkpoint inhibitor for the treatment of malignancies |
AU2017268399B2 (en) | 2016-05-18 | 2023-01-12 | Modernatx, Inc. | mRNA combination therapy for the treatment of cancer |
US20190209652A1 (en) * | 2016-09-23 | 2019-07-11 | Oncosec Medical Incorporated | Modulating responses to checkpoint inhibitor therapy |
US20200123566A1 (en) * | 2017-06-13 | 2020-04-23 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
CN107164538B (zh) * | 2017-07-11 | 2021-03-02 | 复旦大学附属华山医院 | 一种检测calr基因突变的内参扩增引物组合物及其扩增体系 |
CA3093387A1 (en) * | 2018-03-08 | 2019-09-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
TW202039537A (zh) * | 2018-11-27 | 2020-11-01 | 美商昂科賽克醫療公司 | 用於治療癌症之質體建構體和使用方法 |
WO2020123602A1 (en) * | 2018-12-11 | 2020-06-18 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
BR112022002406A2 (pt) | 2019-08-12 | 2022-07-19 | Purinomia Biotech Inc | Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39 |
EP4031168A4 (en) | 2019-09-18 | 2023-10-11 | Intergalactic Therapeutics, Inc. | SYNTHETIC DNA VECTORS AND METHODS OF USE |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
CN112126644B (zh) * | 2020-11-25 | 2021-03-12 | 北京立康生命科技有限公司 | 一种非依赖帽结构下进行细胞外转录的mRNA、呈递细胞及应用 |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
KR102393402B1 (ko) * | 2021-03-26 | 2022-05-04 | (주)와이디생명과학 | 세포 내 존재 단백질과 세포 외부로 분비되는 단백질을 동시 발현하는 이중발현벡터를 포함하는 암의 예방 또는 치료용 조성물 |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
CN116510022B (zh) * | 2022-11-23 | 2023-12-05 | 武汉滨会生物科技股份有限公司 | 一种用于抗肿瘤的组合物、重组质粒组合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004500047A (ja) | 1999-10-20 | 2004-01-08 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | キメラ免疫原性組成物およびこれらをコードする核酸 |
JP2007501283A (ja) | 2003-05-30 | 2007-01-25 | ユニバーシティ オブ サウス フロリダ | 悪性腫瘍を治療する方法 |
JP2009544310A (ja) | 2007-05-14 | 2009-12-17 | インダストリー−ユニバーシティ コオペレーション ファウンデーション ヨンセイ ユニバーシティ | Il−12及びil−23の効率的な共同発現方法 |
US20100158930A1 (en) | 2006-10-19 | 2010-06-24 | Sunbio Biotech Pharmaceuticals (Tianjin) Co., Ltd. | Hpv antigen fusion protein vaccine compositions and uses thereof |
JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ,インコーポレーテッド | IL‐15とIL‐15Rαとの複合体及びその使用 |
JP2012504959A (ja) | 2008-10-08 | 2012-03-01 | イントレキソン コーポレーション | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
EP0803573A1 (en) * | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
JP2002541855A (ja) | 1999-04-21 | 2002-12-10 | ジェンザイム・コーポレーション | 免疫調節分子コード核酸を含むアデノウイルスベクター |
AU6120600A (en) * | 1999-06-08 | 2000-12-28 | Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
US6714816B1 (en) * | 2000-02-22 | 2004-03-30 | University Of South Florida | Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo |
AU3958101A (en) * | 2000-03-15 | 2001-09-24 | Univ Pohang | Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
DE10248141B4 (de) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
US8802643B1 (en) | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
US9273300B2 (en) | 2007-02-07 | 2016-03-01 | Strike Bio, Inc | Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy |
MX362866B (es) | 2012-05-25 | 2019-02-20 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn. |
JP2017518764A (ja) | 2014-04-25 | 2017-07-13 | ストライク バイオ インコーポレイテッド | 癌の処置のための多標的指向RNAi |
CA2981474A1 (en) | 2015-03-31 | 2016-10-06 | Oncosec Medical Incorporated | Systems and methods for improved tissue-sensing based electroporation |
CN109561691A (zh) | 2016-06-07 | 2019-04-02 | 太平洋心肺血研究所 | 用于治疗癌症的组合物和方法 |
US20200123566A1 (en) | 2017-06-13 | 2020-04-23 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
-
2016
- 2016-12-16 US US16/062,983 patent/US11713467B2/en active Active
- 2016-12-16 JP JP2018532285A patent/JP7079729B2/ja active Active
- 2016-12-16 SG SG11201805162VA patent/SG11201805162VA/en unknown
- 2016-12-16 KR KR1020187020538A patent/KR20190031424A/ko not_active Application Discontinuation
- 2016-12-16 SG SG10201913163PA patent/SG10201913163PA/en unknown
- 2016-12-16 AU AU2016369608A patent/AU2016369608B2/en active Active
- 2016-12-16 CN CN201680081690.5A patent/CN109642240A/zh active Pending
- 2016-12-16 WO PCT/US2016/067388 patent/WO2017106795A1/en active Application Filing
- 2016-12-16 CA CA3009123A patent/CA3009123A1/en active Pending
- 2016-12-16 EP EP16876875.2A patent/EP3390643B8/en active Active
- 2016-12-16 IL IL299646A patent/IL299646A/en unknown
-
2018
- 2018-06-14 IL IL260039A patent/IL260039B2/en unknown
-
2020
- 2020-09-25 US US17/032,034 patent/US20210062218A1/en active Pending
-
2022
- 2022-05-23 JP JP2022083896A patent/JP2022116129A/ja active Pending
-
2023
- 2023-05-02 AU AU2023202722A patent/AU2023202722A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004500047A (ja) | 1999-10-20 | 2004-01-08 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | キメラ免疫原性組成物およびこれらをコードする核酸 |
JP2007501283A (ja) | 2003-05-30 | 2007-01-25 | ユニバーシティ オブ サウス フロリダ | 悪性腫瘍を治療する方法 |
US20100158930A1 (en) | 2006-10-19 | 2010-06-24 | Sunbio Biotech Pharmaceuticals (Tianjin) Co., Ltd. | Hpv antigen fusion protein vaccine compositions and uses thereof |
JP2009544310A (ja) | 2007-05-14 | 2009-12-17 | インダストリー−ユニバーシティ コオペレーション ファウンデーション ヨンセイ ユニバーシティ | Il−12及びil−23の効率的な共同発現方法 |
JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ,インコーポレーテッド | IL‐15とIL‐15Rαとの複合体及びその使用 |
JP2012504959A (ja) | 2008-10-08 | 2012-03-01 | イントレキソン コーポレーション | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Non-Patent Citations (4)
Title |
---|
J. Immunol., 2008, Vol.180, pp.2099-2106 |
J. Interferon Cytokine Res., 1999, Vol.19, pp.235-241 |
pCI-neo Mammalian Expression Vector (Instructions for use of product E1841), 2009, Promega Corporation |
PLoS ONE, 2011, Vol.6, Issue 4, e18556 (pp.1-8) |
Also Published As
Publication number | Publication date |
---|---|
WO2017106795A1 (en) | 2017-06-22 |
IL260039B2 (en) | 2023-06-01 |
EP3390643B1 (en) | 2023-06-28 |
KR20190031424A (ko) | 2019-03-26 |
AU2016369608B2 (en) | 2023-02-02 |
CN109642240A (zh) | 2019-04-16 |
AU2023202722A1 (en) | 2023-05-18 |
IL260039A (en) | 2018-07-31 |
JP2022116129A (ja) | 2022-08-09 |
EP3390643A4 (en) | 2019-08-28 |
EP3390643B8 (en) | 2023-08-02 |
JP2018537989A (ja) | 2018-12-27 |
IL299646A (en) | 2023-03-01 |
US20190153469A1 (en) | 2019-05-23 |
SG10201913163PA (en) | 2020-03-30 |
US20210062218A1 (en) | 2021-03-04 |
SG11201805162VA (en) | 2018-07-30 |
US11713467B2 (en) | 2023-08-01 |
EP3390643A1 (en) | 2018-10-24 |
CA3009123A1 (en) | 2017-06-22 |
AU2016369608A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7079729B2 (ja) | 異種タンパク質発現のためのプラスミド構築物及びその使用方法 | |
US20210369813A9 (en) | Modulating responses to checkpoint inhibitor therapy | |
JP7111384B2 (ja) | 悪性腫瘍の治療に対する方法 | |
US20200123566A1 (en) | Multigene construct for immune-modulatory protein expression and methods of use | |
JP2023017930A (ja) | 免疫調節タンパク質発現のための多重遺伝子構築物および使用方法 | |
TW202039537A (zh) | 用於治療癌症之質體建構體和使用方法 | |
KR20190092371A (ko) | 섬유아세포 활성화 단백질을 표적화하는 최적화된 합성 컨센서스 면역원성 조성물 | |
EP3740226A2 (en) | Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same | |
US20240075145A1 (en) | Electrotransfer methods for treating tumors | |
CN117417894A (zh) | 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180709 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180816 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191122 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191122 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210506 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220321 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220426 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220523 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7079729 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |